Document resource
Limited treatment options and therapy resistance make pancreatic ductal adenocarcinoma (PDAC) one of the cancer types with the poorest prognosis and survival rates.1 Currently, the standard of care for PDAC primarily involves chemotherapy, and immunotherapy has yet to show significant benefits in this context.2